www.casipharmaceuticals.com Open in urlscan Pro
192.169.150.185  Public Scan

Form analysis
0 forms found in the DOM

Text Content

NASDAQ: CASI | 中文 | Contact Us


 * CASI

   
 * Menu

 * About Us
   
   * BACK
   
   * Management Team
   * Board of Directors
   * Corporate Governance
   * Career Opportunities
 * Product
 * Pipeline
   
   * BACK
   
   * BI-1206
   * CB-5339
   * CID-103
   * Octreotide
   * Thiotepa
   * Other Assets
 * Partnering
 * Clinical Trials
 * Investor Center
   
   * BACK
   
   * News
   * Events
   * Annual Meeting
   * Analyst Coverage
   * SEC Filings
 * Menu


 * CASI PHARMACEUTICALS ANNOUNCES CHINA MARKET APPROVAL OF MELPHALAN
   HYDROCHLORIDE FOR INJECTION (EVOMELA®).
   
   Learn More


 * BRINGING LIFE-CHANGING THERAPEUTICS TO CHINA AND THE WORLD.
   
   Learn More




CASI NEWS


CASI PHARMACEUTICALS ENTERS INTO SUBLICENSE AGREEMENT WITH TIANSHI
PHARMACEUTICALS FOR ANTI-CD38 MONOCLONAL ANTIBODY (MAB) CID-103 IN AUTOIMMUNE
FIELD

May 24, 2022

ROCKVILLE, MD. and BEIJING, China (May 24, 2022) CASI Pharmaceuticals, Inc.
(NASDAQ: CASI), a U.S. biopharmaceutical company focused on developing and
commercializing innovative therapeutics and pharmaceutical products, today
announced the signing of a Sublicense Agreement with Beijing Tianshi Tongda
Pharmaceuticals Technology Co., Ltd., (“TIANSHI”) a clinical stage
pharmaceutical company organized and existing under the laws of the People’s
Republic of China (“PRC”). The Sublicense Agreement grants TIANSHI an exclusive,
perpetual, worldwide license for the investigational anti-CD38 monoclonal
antibody (Mab), CID-103, in the treatment, prevention, and diagnosis of
autoimmune diseases, conditions, and disorders in humans.

Read the press release.



CASI PHARMACEUTICALS ANNOUNCES FIRST QUARTER 2022 FINANCIAL RESULTS

May 12, 2022

ROCKVILLE, MD. and BEIJING, China (May 12, 2022) CASI Pharmaceuticals, Inc.
(Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and
commercializing innovative therapeutics and pharmaceutical products, today
reported financial results for the first quarter of 2022.

Read the press release.


Press Release

December 15, 2022

CASI Pharmaceuticals’ Partner Juventas Announces New Drug Application For CNCT19
Accepted By China National Medical Products Administration


Read More

Press Release

November 14, 2022

CASI PHARMACEUTICALS ANNOUNCES THIRD QUARTER 2022 FINANCIAL RESULTS


Read More

Press Release

September 23, 2022

CASI PHARMACEUTICALS ANNOUNCES EXIT OF JUVENTAS INVESTMENT TO STRENGTHEN BALANCE
SHEET


Read More

View All Email Alerts |


U.S. FDA-APPROVED PRODUCT


EVOMELA®

Multiple Myeloma


CLINICAL CANDIDATES


CNTC19

Hematological Malignancies


BI-1206

Non-Hodgkin's Lymphoma and Solid Tumors


CB-5339

AML, MDS and Solid Tumors


CID-103

Multiple Myeloma
Learn more about our product pipeline



ABOUT US

CASI is a U.S. NASDAQ-listed biopharmaceutical company with a platform to
develop and accelerate the launch of pharmaceutical products and innovative
therapeutics in China, the U.S., and throughout the world. We have offices in
Rockville, Maryland, and a wholly owned subsidiary in Beijing, China, through
which substantially all of our operations are conducted.

Learn More


DOWNLOADS


Corporate Presentation

EVOMELA® (melphalan) for Injection is proprietary to Acrotech Biopharma Inc. and
its affiliates.

© 2022 CASI Pharmaceuticals Inc.
All Rights Reserved.

 * About Us
 * Partnering
 * Clinical Trials
 * Investor Center
 * Privacy